Recent Updates — RZLT

Rezolute, Inc. announced the completion of patient enrollment in its open-label Phase 3 upLIFT registrational study evaluating ersodetug for tumor hyperinsulinism. The trial enrolled 16 participants with insulinoma or non-islet cell tumors experiencing uncontrolled hypoglycemia. Topline data from the pivotal trial are expected by mid-December 2026. Earlier results indicated that seven of eight initial participants met the primary endpoint, achieving significant reductions in glucose infusion rates. Rezolute is a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by hyperinsulinism.

The FDA recommended a pre-BLAs meeting as a precursor to submitting a Biologics License Application (BLA) for ersodetug in congenital hyperinsulinism, following a preliminary review of Phase 3 sunRIZE data. Although the trial missed its primary endpoint due to lack of statistical significance in self-monitored blood glucose reductions, the Agency acknowledged clinically relevant improvements in continuous glucose monitoring metrics and encouraged the BLA submission strategy. Rezolute also expects topline results from the upLIFT study for tumor hyperinsulinism this quarter, which could trigger a separate pre-BLA meeting. The company operates as a late-stage biotechnology firm focused on treating refractory hypoglycemia caused by hyperinsulinism.

Rezolute, Inc. reported financial results for the fourth quarter and full fiscal year ended June 30, 2026. Cash, cash equivalents, and investments totaled $107.8 million as of June 30, 2026. Full-year research and development expenses were $53.8 million, while general and administrative expenses rose to $29.2 million due to increased stock-based compensation and professional fees. The company reported a full-year net loss of $77.6 million compared to $74.4 million in fiscal 2025. Clinically, the Phase 3 upLIFT study for tumor hyperinsulinism is ongoing with topline results expected before year-end 2026, while the sunRIZE study data for congenital HI remains under FDA review following a primary endpoint miss. Rezolute operates in the biotechnology industry, developing ersodetug as an investigational therapy for refractory hypoglycemia caused by hyperinsulinism.